Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Aytu Biopharma (AYTU) over the last 17 years, with Sep 2025 value amounting to -10.83%.

  • Aytu Biopharma's EBITDA Margin fell 522.00% to -10.83% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.19%, marking a year-over-year decrease of 968.00%. This contributed to the annual value of -11.79% for FY2025, which is 845.00% down from last year.
  • Latest data reveals that Aytu Biopharma reported EBITDA Margin of -10.83% as of Q3 2025, which was up 78.50% from -50.37% recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's EBITDA Margin ranged from a high of 16.78% in Q4 2023 and a low of -220.76% during Q1 2022.
  • Over the past 3 years, Aytu Biopharma's median EBITDA Margin value was -10.45% (recorded in 2024), while the average stood at -10.94%.
  • As far as peak fluctuations go, Aytu Biopharma's EBITDA Margin crashed by 13,159bps in 2021, and later spiked by 18,311bps in 2023.
  • Aytu Biopharma's EBITDA Margin (Quarterly) stood at -48.84% in 2021, then spiked by 2,270bps to -26.13% in 2022, then soared by 4,292bps to 16.78% in 2023, then crashed by 2,723bps to -10.45% in 2024, then tumbled by 522bps to -10.83% in 2025.
  • Its EBITDA Margin stands at -10.83% for Q3 2025, versus -50.37% for Q2 2025 and 13.12% for Q1 2025.